Regen7 Molecule is a discovery resulting from several years of research works conducted by Polish scientists working at Lodz University of Technology and Medical University of Lodz.
It all goes back to the 90s, when chemists working at Lodz University of Technology began their work on using selected pyridinium salts as possible therapeutic agents. Studies were conducted in cooperation with biochemists, microbiologists and clinicians from Medical University of Lodz. These works lead to unexpected discoveries, characterised by considerable cognitive and application significance. It was shown that the selected 3-substituted 1-methylpyridinium salts reveal incredibly interesting properties. Particular consideration was given to the activity of PP vitamin metabolite (currently known as Regen7 Molecule). This substance has been already known for years, however, its therapeutic function has never been tested before. Perseverance and harmonious cooperation between Polish scientists lead to a situation, where not only the mechanism underlying the activity of this compound was known, but also its therapeutic function was assessed during application dermatological tests. All in all, mutual efforts of researchers from Lodz University of Technology and Medical University of Lodz resulted in the establishment of PHARMENA Company, as well as in elaboration and marketing innovative products, based on Regen7 Molecule.
Regen7 Molecule is a unique active, patent protected substance (patent owned by PHARMENA Company, P-330768; EP 1147086). This substance is present only in PHARMENA products.